Wang et al. and Remdesivir: did Wang's LANCET publication May 2020 below blow Remdesivir out of the water as ineffective and deadly yet Fauci & NIH that day made Remdesiver standard of care? Yes!

by Paul Alexander

Wang's trial should have ensured Remdesivir was DOA, but NIH & Fauci disregarded this study that was released SAME day, 'remdesivir was not associated with statistically significant clinical benefit'



‘Between Feb 6, 2020, and March 12, 2020, 237 patients were enrolled and randomly assigned to a treatment group (158 to remdesivir and 79 to placebo); one patient in the placebo group who withdrew after randomisation was not included in the ITT population. Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1·23 [95% CI 0·87–1·75]). Although not statistically significant, patients receiving remdesivir had a numerically faster time to clinical improvement than those receiving placebo among patients with symptom duration of 10 days or less (hazard ratio 1·52 [0·95–2·43]). Adverse events were reported in 102 (66%) of 155 remdesivir recipients versus 50 (64%) of 78 placebo recipients. Remdesivir was stopped early because of adverse events in 18 (12%) patients versus four (5%) patients who stopped placebo early.


In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits.’